Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is a complex task, with constantly evolving case law and practice on both sides of the Atlantic. In this webinar, AWA’s experts focus on how to create, defend and litigate these patents in Europe and elsewhere.
Patenting Antibody and Cell Therapies – What to Do and What Not to Do
You may also be interested in:
China’s First AI-Generated Picture Copyright Infringement Case
In November 2023, the Beijing Internet Court issued a first-instance judgment in China’s first “AI-generated picture copyright infringement case”,
EPO launches new PPH agreements with New Zealand and Bahrain
The PPH network continues to expand, and we at AWA remain one step ahead by closely monitoring the new
Increasing Burden of Proof for Trademark Applicants in China
Based on the recent official notices issued by the CNIPA (China National Intellectual Property Administration) about non-use cancellation cases,